Avila Therapeutics Presents Data Demonstrating the Relevance of its Btk Inhibitor, AVL-292, in B Cell Malignancies such as CLL

LONDON & WALTHAM, Mass.--(BUSINESS WIRE)--Avila Therapeutics™, Inc., a biotechnology company developing novel targeted covalent drugs, today announced the presentation of data on AVL-292, a clinical-stage inhibitor of Bruton’s tyrosine kinase (Btk), at the 16th Congress of the European Hematology Association (EHA).